Development of a sensitive indirect competitive enzyme-linked immunosorbent assay for high-throughput detection and risk assessment of aflatoxin B1 in animal-derived medicines
Development of a sensitive indirect competitive enzyme-linked immunosorbent assay for high-throughput detection and risk assessment of aflatoxin B1 in animal-derived medicines
复制标题
开发灵敏的间接竞争酶联免疫吸附测定法,用于动物源性药物中黄曲霉毒素 B1 的高通量检测和风险评估
DOI:
10.1016/j.toxicon.2021.04.009
复制
发表时间:
2021-04-27
期刊:
影响因子:
2.8
通讯作者:
Yang, Meihua
中科院分区:
文献类型:
--
作者:
Wang, Changjian;Zhang, Lei;Yang, Meihua
Animal-derived medicine is an important part of traditional Chinese medicine (TCM). Studies have shown that many animal-derived medicinal products are susceptible to contaminate of aflatoxins, nevertheless, the rapid detection for animal-derived medicine is prone to be ignored. Here we developed a sensitive indirect competitive enzyme-linked immunosorbent assay (icELISA) for rapid screening of aflatoxin B-1 (AFB(1)) in ground beetle, cockroach, silkworm and earthworm. The sensitivity of the icELISA method was significantly enhanced. The IC50 for the four animal-derived medicinal samples ranged from 0.092 to 0.135 ng mL(-1); the limit of detection (LOD) was 0.008-0.020 ng mL(-1). To obtain high accuracy, the extraction solution and time were evaluated. By using this method, a total of 138 samples were investigated, and the detection rates of AFB(1) in ground beetle and earthworm samples were 26.6% and 16.7%, respectively. The result was validated by liquid chromatography combined with tandem mass spectrometry, and an excellent correlation was observed between the two datasets, with a R-2 value of 0.999. Our results indicate that the proposed method can be used for the rapid detection of AFB(1) in animal-derived medicine. Furthermore, the quantitative risk assessment was conducted for ground beetle and earthworm based on the results, demonstrating that the intake of AFB(1) in ground beetle had a slight threat to the risk of cancer.